Xilio Therapeutics, Inc.
XLO
$0.6844
-$0.0154-2.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -56.22M | -54.30M | -58.24M | -62.80M | -65.53M |
| Total Depreciation and Amortization | 1.63M | 1.70M | 1.64M | 1.72M | 1.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.31M | 6.14M | 6.44M | 6.87M | 7.18M |
| Change in Net Operating Assets | 32.95M | 67.57M | 31.78M | 36.57M | 39.21M |
| Cash from Operations | -13.33M | 21.10M | -18.38M | -17.65M | -17.35M |
| Capital Expenditure | -438.00K | -58.00K | -36.00K | -30.00K | -21.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -438.00K | -58.00K | -36.00K | -30.00K | -21.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.00K | -28.00K | -3.38M | -5.07M | -7.31M |
| Issuance of Common Stock | 13.08M | 33.10M | 32.58M | 24.43M | 24.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 47.32M | -- | -- | -- | -- |
| Cash from Financing | 60.39M | 33.07M | 29.20M | 19.36M | 17.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.63M | 54.12M | 10.78M | 1.68M | -239.00K |